BioPharma
Generative AI In Pharma: Major Opportunities And Hurdles
Among the pharmaceutical DX-digital transformation professionals, 67% responded that they were not ready when asked about how ready the life sciences sector is to effectively go ahead and leverage generative AI in terms of infrastructure, regulatory considerations, and expertise....
BioPharma
Global Biopharma Market To Hit $566B By 2032 Amid Challenges
The value of the global biopharmaceutical industry is expected to rise significantly, from $263 billion in 2022 to $566 billion by 2032, representing a compound annual growth rate of about 8% from 2023 to 2032.
This growth is mostly being...
BioPharma
Thermo Fisher Partners with X-ELIO for Renewable Energy
Thermo Fisher Scientific has taken a significant step toward achieving its sustainability goals by signing a 10-year virtual power purchase agreement (VPPA) with renewable energy developer X-ELIO. This agreement supports the Lorca solar project, which is set to become...
BioPharma
Oncology Precision Medicine: Challenges and Opportunities for Biopharmaceutical Companies
With a growing shift towards tailored therapies for cancer treatment, personalized medicine emerges as a groundbreaking solution. Cancer has been a major cause of concern among healthcare professionals and patients at the global level. As per the report of...
BioPharma
Transforming healthcare: 4D Lifetec’s revolutionary approach to early cancer detection
In the rapidly advancing landscape of healthcare, 4D Lifetec emerges as a trailblazer, aiming to redefine the paradigm of early cancer detection. At the forefront of this innovative journey is the Lifetest™, a user-friendly and proprietary immunological liquid biopsy...
BioPharma
2024 May Have Regulations Change In The Biopharma Backdrop
The scenario is that the regulators are all ramping up pressure when it comes to the biopharma industry in 2024. Pharma companies not only happen to need to jump through new hoops when it comes to an increasingly intricate...
BioPharma
M&A Revival In The Biopharmaceutical Sector Back On Track
It is worth noting that the biopharmaceutical sector has gone on to experience a revival when it comes to mergers and acquisitions in the second half of 2023. One can see three major reasons resulting in this uptick in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
